Overview

Genome Editing Market is poised to value over USD 13.6 billion by 2027 end at a CAGR of over 16.8% during the forecast period 2020 to 2027.

The rising support from governments for conducting researches on genome editing which has resulted in the growth of production of genetically modified plants is the primary factor responsible for the growth of the market. Furthermore, the market growth os based on factors such as growing prevalence of chronic diseases like cancer.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Genome Editing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Genome Editing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Genome Editing Market:

• Thermo Fisher Scientific
• Merck
• Horizon Discovery
• Genscript
• Sangamo Therapeutics
• Lonza
• Editas Medicine
• Crispr Therapeutics
• Eurofins Scientific
• Precision Biosciences
• Oxford Genetics
• Intellia Therapeutics
• Synthego
• Vigene Biosciences
• Epigenie
• Integrated DNA Technologies
• New England Biolabs
• Origene Technologies
• Transposagen Biopharmaceuticals
• Creative Biogene

(Note: The list of the major players will be updated with the latest market scenario and trends)

Genome Editing Market Segmentation:

By Technology
• CRISPR 
• TALEN
• ZFN 
• Antisense 
• Other Technologies 

By Product and Service 
• Reagents & Consumables 
• Software & Systems 
• Services

By Application 
• Cell Line Engineering
• Genetic Engineering
  o Animal Genetic Engineering
  o Plant Genetic Engineering
• Diagnostic Applications
• Drug Discovery & Development
• Other Applications

By End-User
• Pharmaceutical Companies
• Biotechnology Companies
• Academic & Government Research Institutes

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Genome Editing Market By Technology, By Product and Service, By Application, By End-User and By Region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to:
sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Global Genome Editing Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Genome Editing Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Genome Editing Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Genome Editing Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million)
   7.1. CRISPR 
   7.2. TALEN
   7.3. ZFN 
   7.4. Antisense 
   7.5. Other Technologies 

8. Global Genome Editing Market, By Product and Service Historical Analysis and Forecast 2020-2027 (USD Million)  
   8.1. Reagents & Consumables 
   8.2. Software & Systems 
   8.3. Services

9. Global Genome Editing Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)  
   9.1. Cell Line Engineering
   9.2. Genetic Engineering
        9.2.1. Animal Genetic Engineering
        9.2.2. Plant Genetic Engineering
   9.3. Diagnostic Applications
   9.4. Drug Discovery & Development
   9.5. Other Applications

10. Global Genome Editing Market, By End-User Historical Analysis and Forecast 2020-2027 (USD Million)  
    10.1. Pharmaceutical Companies
    10.2. Biotechnology Companies
    10.3. Academic & Government Research Institutes

11. North America Genome Editing Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          11.2.1. U.S.A
          11.2.2. Canada
          11.2.3. Mexico
    11.3. Market Size (USD Million) Forecast for North America 2020-2027

12. Latin America Genome Editing Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2020-2027

13. Europe Genome Editing Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2020-2027

14. Asia Pacific Genome Editing Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

15. Middle East and Africa Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          15.2.1. Saudi Arabia
          15.2.2. UAE
          15.2.3. South Africa
          15.2.4. Egypt
    15.3. Market Size (USD Million) Forecast for MEA 2020-2027

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4. North America - Market Share Analysis and Key Regional Players
    16.5. Europe - Market Share Analysis and Key Regional Players
    16.6. Asia Pacific - Market Share Analysis and Key Regional Players
    16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    17.1. Thermo Fisher Scientific
          17.1.1. Company Overview
          17.1.2. Product Portfolio
          17.1.3. SWOT Analysis
          17.1.4. Financial Overview
          17.1.5. Strategic Overview
    17.2. Merck
          17.2.1. Company Overview
          17.2.2. Product Portfolio
          17.2.3. SWOT Analysis
          17.2.4. Financial Overview
          17.2.5. Strategic Overview 
    17.3. Horizon Discovery
          17.3.1. Company Overview
          17.3.2. Product Portfolio
          17.3.3. SWOT Analysis
          17.3.4. Financial Overview
          17.3.5. Strategic Overview
    17.4. Genscript
          17.4.1. Company Overview
          17.4.2. Product Portfolio
          17.4.3. SWOT Analysis
          17.4.4. Financial Overview
          17.4.5. Strategic Overview
    17.5. Sangamo Therapeutics
          17.5.1. Company Overview
          17.5.2. Product Portfolio
          17.5.3. SWOT Analysis
          17.5.4. Financial Overview
          17.5.5. Strategic Overview          
    17.6. Lonza
          17.6.1. Company Overview
          17.6.2. Product Portfolio
          17.6.3. SWOT Analysis
          17.6.4. Financial Overview
          17.6.5. Strategic Overview      
    17.7. Editas Medicine
          17.7.1. Company Overview
          17.7.2. Product Portfolio
          17.7.3. SWOT Analysis
          17.7.4. Financial Overview
          17.7.5. Strategic Overview
    17.8. Crispr Therapeutics
          17.8.1. Company Overview
          17.8.2. Product Portfolio
          17.8.3. SWOT Analysis
          17.8.4. Financial Overview
          17.8.5. Strategic Overview 
    17.9. Eurofins Scientific
          17.9.1. Company Overview
          17.9.2. Product Portfolio
          17.9.3. SWOT Analysis
          17.9.4. Financial Overview
          17.9.5. Strategic Overview 
    17.10.Precision Biosciences
          17.10.1. Company Overview
          17.10.2. Product Portfolio
          17.10.3. SWOT Analysis
          17.10.4. Financial Overview
          17.10.5. Strategic Overview
    17.11.Oxford Genetics
          17.11.1. Company Overview
          17.11.2. Product Portfolio
          17.11.3. SWOT Analysis
          17.11.4. Financial Overview
          17.11.5. Strategic Overview          
    17.12.Intellia Therapeutics
          17.12.1. Company Overview
          17.12.2. Product Portfolio
          17.12.3. SWOT Analysis
          17.12.4. Financial Overview
          17.12.5. Strategic Overview      
    17.13.Synthego
          17.13.1. Company Overview
          17.13.2. Product Portfolio
          17.13.3. SWOT Analysis
          17.13.4. Financial Overview
          17.13.5. Strategic Overview
    17.14.Vigene Biosciences
          17.14.1. Company Overview
          17.14.2. Product Portfolio
          17.14.3. SWOT Analysis
          17.14.4. Financial Overview
          17.14.5. Strategic Overview 
    17.15.Epigenie
          17.15.1. Company Overview
          17.15.2. Product Portfolio
          17.15.3. SWOT Analysis
          17.15.4. Financial Overview
          17.15.5. Strategic Overview 
    17.16.Integrated DNA Technologies
          17.16.1. Company Overview
          17.16.2. Product Portfolio
          17.16.3. SWOT Analysis
          17.16.4. Financial Overview
          17.16.5. Strategic Overview
    17.17.New England Biolabs
          17.17.1. Company Overview
          17.17.2. Product Portfolio
          17.17.3. SWOT Analysis
          17.17.4. Financial Overview
          17.17.5. Strategic Overview
    17.18.Origene Technologies
          17.18.1. Company Overview
          17.18.2. Product Portfolio
          17.18.3. SWOT Analysis
          17.18.4. Financial Overview
          17.18.5. Strategic Overview
    17.19.Transposagen Biopharmaceuticals
          17.19.1. Company Overview
          17.19.2. Product Portfolio
          17.19.3. SWOT Analysis
          17.19.4. Financial Overview
          17.19.5. Strategic Overview
    17.20.Creative Biogene
          17.20.1. Company Overview
          17.20.2. Product Portfolio
          17.20.3. SWOT Analysis
          17.20.4. Financial Overview
          17.20.5. Strategic Overview

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client
 

Tables

Figures